Fidaxomicin

Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of

Optimer Pharmaceuticals Obtains Additional Fidaxomicin Patent - Yahoo! Finance 2011

"Fidaxomicin does kill the bug, but in terms of recurrence, it doesn't disturb the normal balance of flora in the intestines," he said.

Yahoo! News: Business - Opinion 2011

Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of

Optimer Pharmaceuticals Obtains Additional Fidaxomicin Patent - Yahoo! Finance 2011

We are lifting the embargo immediately for the Original Article, "Fidaxomicin versus Vancomycin for Clostridium difficile Infection," and editorial, "The Search for Effective Treatment of Clostridium difficile Infection," scheduled to appear in tomorrow's February 3 issue.

unknown title 2011

Fidaxomicin may facilitate the return of the normal physiological conditions in the colon and reduce the probability of CDI recurrence.

TradingMarkets 2010

Fidaxomicin is the first in a new class of antibiotics called macrocycles, which inhibit the bacterial enzyme RNA polymerase, resulting in the death of C. difficile.

TradingMarkets 2010

Fidaxomicin use will be limited to CDI treatment failures.

BloggingStocks 2010

Most notably, Fidaxomicin showed a clinically meaningful reduction in recurrence rates and higher global cure rates compared to Vancocin in both strain type subgroups.

TradingMarkets 2010

"Fidaxomicin offers potential advantages over existing therapies as a single agent that can provide a high cure rate and fewer recurrences for Clostridium difficile infection," said Dr. Crook, M.D.,

TradingMarkets 2010

Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection.

TradingMarkets 2010